

NZX Announcement

11 September 2020

JULIET HULL ELECTED NON-EXECUTIVE DIRECTOR

Truscreen Group Limited (NZX:TRU) (Truscreen or Company) is pleased to confirm the election of Ms Juliet Hull as a non-executive director of Truscreen at yesterday's meeting of shareholders.

Ms Hull is the NZ General Manager/Country Director of Johnson & Johnson Medical (J & J), a director of the ANZ Johnson & Johnson Medical Executive Board, a director of MTANZ (Medical Technology Association of NZ) and a member of both the APAC Regional Leadership team for J & J's Orthopaedics and Ethicon Divisions.

Ms Hull is a senior executive with more than 20 years' experience in Asia Pacific markets in Healthcare sales, marketing and leadership.

Ms Hull holds a Master of Business and Administration (Macquarie Graduate School of Management, Sydney, Australia) and Bachelor of Nursing (Auckland University of Technology), Auckland, New Zealand).

Tony Ho, Chairman commented “ *we are delighted to welcome Ms Juliet Hull to the Board of Truscreen. Her enthusiasm and healthcare expertise in the Asia Pacific region will be invaluable to the Company.*”

Mr Con Hickey, retired from the Board at yesterday's Annual Meeting. The board thanks Mr Con Hickey for his significant contribution to the Company.

-ENDS-

For more information, visit www.truscreen.com or contact:

Anthony Ho
Chairman
tonyho@truscreen.com



truscreen
a world without
cervical cancer

About TruScreen:

TruScreen cervical cancer screening device [offers the latest technology](#) in cervical screening, providing real-time, accurate detection of precancerous and cancerous cervical cells to help improve the health and well-being of women around the world.

TruScreen's real-time cervical cancer technology utilises a digital wand which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissues. A sophisticated proprietary algorithm framework is utilised to detect pre-cancerous change, or cervical intra-epithelial neoplasia (CIN), by optical and electrical measurement of cervical tissue.

TruScreen offers an alternative approach to cervical screening, [resolving many of the ongoing issues](#) with conventional Pap tests, including failed samples, poor patient follow-up, patient discomfort and the need for supporting laboratory infrastructure. As such, TruScreen's target [market](#) is low and middle-income countries where no large-scale cervical cancer screening programs and infrastructure are in place, such as China, Mexico, Africa, Russia and India. TruScreen's cervical cancer screening device is CE-marked and certified for use throughout Europe and CFDA approved for sale in China. The global market potential for TruScreen is significant.